Hematology

Challenge: An investor and asset manager was considering an investment in a European biotech company with one development product for hemophilia and another approved OTC product in an unrelated...

Challenge: A venture-backed US biotech company was developing a preclinical biologic for haematological indications and wished to quantify the commercial opportunity for the product in treating...

Challenge: A US-based biotech company developing a novel biologic which impacts iron metabolism, wanted help deciding which disease and patient groups would make the best lead indication for...

Challenge: Our client was developing a novel iron treatment with potential to be best-in-class for iron deficiency anemia (IDA). The product used nanotechnology to mimic the natural structure of...

Challenge: An investor group was facing its first potential deal in the pharmaceuticals sector. It had pre-negotiated a deal with a group that had invented an approach to treating...

Challenge: Our client was a publicly-traded clinical-stage biopharmaceutical company using an epigenetic approach modulate gene expression in tumor and immune cells to treat cancer. Their lead...

Challenge: A leading European university identified a gene therapy for the treatment of haemoglobinopathies. Alacrita was asked to support the Principal Investigator (PI) in developing a Commercial...

Challenge: Our client needed an assessment of the market opportunity and value proposition for a novel anemia therapy in order to facilitate discussions with potential partners.

Challenge: Our diagnostics consultants were asked to develop an ex-US business development strategy and identify sources of non-dilutive finance for a well-backed, venture capital-funded diagnostics...

Challenge: A publicly traded specialty pharma company was considering acquiring a company developing a prescription product for use by surgeons. We were asked to conduct an assessment of the market...

Challenge: An emerging specialty pharma company facing an urgent partnering transaction deadline needed to assess the likely reimbursement and pricing of a new therapy in a crowded haematology...